98%
921
2 minutes
20
Objective: Paravalvular regurgitation is a known complication after transcatheter and sutureless aortic valve replacement. Paravalvular regurgitation also may develop in patients undergoing percutaneous mitral valve replacement. There are few studies on contemporary surgical valve replacement for comparison. We sought to determine the contemporary occurrence of paravalvular regurgitation after conventional surgical valve replacement.
Methods: We performed a single-center retrospective database review involving 1774 patients who underwent valve replacement surgery from April 2004 to December 2012: aortic in 1244, mitral in 386, and combined aortic and mitral in 144. Follow-up echocardiography was performed in 73% of patients. Patients with endocarditis were analyzed separately from noninfectious paravalvular leaks. Statistical comparisons were performed to determine differences in paravalvular regurgitation incidence and survival.
Results: During follow-up, 1+ or greater (mild or more) paravalvular regurgitation occurred in 2.2% of aortic cases and 2.9% of mitral cases. There was 2+ or greater (moderate or more) paravalvular regurgitation in 0.9% of aortic and 2.2% of mitral cases (P = .10). After excluding endocarditis, late noninfectious regurgitation 2+ or greater was detected in 0.5% of aortic and 0.4% of mitral cases (P = .93); there were no reoperations or percutaneous closures for noninfectious paravalvular regurgitation.
Conclusions: In an academic medical center, the overall rate of paravalvular regurgitation is low, and late clinically significant noninfectious paravalvular regurgitation is rare. The benchmark for paravalvular regurgitation after conventional valve replacement is high and should be considered when evaluating patients for transcatheter or sutureless valve replacement.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jtcvs.2015.06.047 | DOI Listing |
Objective: Minimally invasive aortic valve replacement (MIAVR) and transcatheter aortic valve replacement (TAVR) represent less-invasive alternatives to conventional surgical aortic valve replacement. In contrast to Society of Thoracic Surgeons (STS) Database data revealing <10% of all surgical aortic valve replacement procedures are performed via a minimally invasive approach, our center performs a high volume of MIAVR procedures. This propensity-score matched study aims to compare the outcomes of MIAVR versus TAVR in low-risk patients (STS Predicted Risk of Mortality <4%).
View Article and Find Full Text PDFJ Int Med Res
September 2025
Department of Cardiology, Chengdu Second People's Hospital, China.
This case report details the successful use of JenaValve for transcatheter aortic valve implantation in a male patient in his early 50s with severe aortic regurgitation. The patient had multiple comorbidities, including chronic kidney disease and heart failure, increasing the risk of surgical intervention. JenaValve, a second-generation device with unique positioning and anchoring mechanisms, was deployed successfully, resulting in immediate improvements in cardiac function without significant regurgitation or paravalvular leakage.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
September 2025
Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Background: With transcatheter aortic valve implantation (TAVI) now extending to lower-risk and younger patients, optimizing procedural and hemodynamic outcomes is critical. The Myval Octacor, a new balloon-expandable valve (BEV), was developed to improve outcomes by reducing paravalvular regurgitation (PVL), minimizing pacemaker implantation (PPI) rates, and enhancing hemodynamic performance. However, limited data are available comparing Myval Octacor to contemporary self-expanding supra-annular valves (SEVs) Evolut PRO/PRO+ and Acurate Neo2.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
September 2025
Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
We present a 74-year-old female with a history of mechanical aortic and mitral valve implantation and non-Hodgkin lymphoma. She presented with right sided heart failure due to severe functional tricuspid regurgitation and was treated with transcatheter TricValve bicaval system implantation. However, this was complicated by a paravalvular leak of the inferior vena cava prosthesis.
View Article and Find Full Text PDFStruct Heart
September 2025
Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Background: Paravalvular leak (PVL) remains a frequent complication of transcatheter aortic valve replacement (TAVR). The long-term consequences of mild PVL on outcomes have been debated. This study aimed to investigate the clinical and hemodynamic outcomes of mild PVL over a 2-year period.
View Article and Find Full Text PDF